Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice

Journal of Bone and Mineral Research

Volumn 17, Issue 7, 2002, Pages 1256-1263

  Zhang, Jian ^a,b   Dai, Jinlu ^a   Lin, Din Lii ^a   Habib, Paula ^a   Smith, Peter ^a   Murtha, Jill ^a,b   Fu, Zheng ^a   Yao, Zhi ^c   Qi, Yinghua ^d   Keller, Evan T ^a,b,e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d Tianjin Third Central Hospital   (China)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Animal model; Ethanol; Osteoporosis; Osteoprotegerin; RANKL

Indexed keywords

ALCOHOL; CALCIUM; CELL RECEPTOR; GLYCOPROTEIN; OSTEOPROTEGERIN; TNFRSF11B PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR; DEOXYPYRIDINOLINE; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL; ARTICLE; BONE DENSITY; C57BL MOUSE; DRUG EFFECT; FEMUR; MALE; METABOLISM; MOUSE; OSTEOCLAST; OSTEOPOROSIS; PATHOPHYSIOLOGY; ALCOHOLISM; ANIMAL MODEL; BONE ATROPHY; BONE MINERAL; COLONY FORMING UNIT F; COLONY FORMING UNIT GM; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST CULTURE; NONHUMAN; OSTEOBLAST; URINALYSIS;

ANIMALS; BONE DENSITY; CALCIUM; ETHANOL; FEMUR; GLYCOPROTEINS; MALE; MICE; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; ANIMAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035991259     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.7.1256     Document Type: Article

References (45)

1. Effects of alcohol abuse on bone
2. Bone disease in alcohol abuse
3. Deranged bone mineral metabolism in chronic alcoholism
4. Bone and mineral metabolism and chronic alcohol abuse
5. Bone mineral density and abstention-induced changes in bone and mineral metabolism in noncirrhotic male alcoholics
6. Pathogenesis of osteoporosis
7. Long-term bone loss in men: Effects of genetic and environmental factors
8. Ethanol inhibits human bone cell proliferation and function in vitro
9. Bone morphometry in alcoholics
10. Ethanol reduces bone formation and may cause osteoporosis
11. Direct effects of ethanol on bone resorption and formation in vitro
12. Effect of alcohol ingestion on bone and mineral metabolism in rats
13. Effects of ethanol on bone cells in vitro resulting in increased resorption
14. Bone resorption by osteoclasts
15. Osteoclast generation
16. Alcohol-induced bone disease in the absence of severe chronic liver damage
17. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice
18. Diet and ethanol modulate immune responses in young C57BL/6 mice
19. Chronic ethanol consumption prior to retrovirus infection alters cytokine production by thymocytes during murine AIDS
20. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence
21. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: A specific marker of the differentiated osteoclast that is regulated by calcitonin
22. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats
23. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee
24. The comparability of ethanol concentrations in peripheral blood and saliva. The phenomenon of variation in saliva to blood concentration ratios
25. The validity of urine alcohol analysis in drunk drivers
26. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
27. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines
28. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
29. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
30. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
31. Osteoprotegerin mitigates tail suspension-induced osteopenia
32. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
33. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis
34. The effect of a single dose of osteoprotegerin in postmenopausal women
35. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
36. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
37. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
38. Osteoprotegerin diminishes advanced bone cancer pain
39. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis
40. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice
41. Longitudinal study of bone metabolism after ethanol withdrawal in alcoholic patients
42. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3
43. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
44. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor
45. Inhibition of osteoblastic cell differentiation by conditioned medium derived from the human prostatic cancer cell line PC-3 in vitro